Most people researching retatrutide side effects arrive expecting the familiar list: nausea, vomiting, diarrhoea, constipation. That list is accurate — but it is now incomplete. The phase 3 TRIUMPH data surfaced an adverse event that did not appear in the phase 2 trial at all, and it has nothing to do with the gut. It's called dysesthesia, and at the top dose it was reported by roughly one in five participants.

Because retatrutide is investigational and not TGA-approved, there is no Australian Product Information or Consumer Medicine Information document listing its side effects. Australians reading about this drug are working from overseas trial reporting only — which makes knowing what's actually in the phase 3 data more useful than usual.

The retatrutide side effect that wasn't in phase 2

In the phase 3 TRIUMPH-4 trial — 445 participants with obesity and knee osteoarthritis, randomised 1:1:1 to retatrutide 9 mg, 12 mg or placebo — dysesthesia was reported in 8.8% of the 9 mg group and 20.9% of the 12 mg group, against 0.7% on placebo, according to reporting on Lilly's data by BioSpace.

Dysesthesia means an altered or unpleasant sense of touch: tingling, burning, numbness, or skin that feels abnormally sensitive to ordinary contact. It is a sensory symptom, not a gastrointestinal one.

The detail that makes it notable is the dose-response gap and the novelty. This was not a finding in the phase 2 trial published in the New England Journal of Medicine in 2023. It emerged in phase 3, at higher doses, over longer exposure — which is exactly the kind of thing larger and longer trials exist to catch.

What Lilly has said, and what hasn't been established

Lilly has said the dysesthesia events did not appear to drive treatment discontinuation, and they have been characterised as generally mild. That is the company's own account of topline data.

Two caveats deserve stating plainly. First, TRIUMPH-4's detailed results were announced via press release in December 2025; the full peer-reviewed publication with the complete severity breakdown, time-to-onset and resolution data was still pending at the time of that reporting. Second, a mechanism has not been established — nobody has published an explanation for why a triple agonist would produce sensory symptoms. Until the full dataset is in a journal, "mild and self-limiting" is a claim to be read as preliminary, not settled. More detail on how the programme is structured is on our clinical trials page.

The gastrointestinal numbers, in full

The core side-effect profile still looks like an incretin drug's. In TRIUMPH-1, across the 4 mg, 9 mg and 12 mg doses against placebo:

  • Nausea: 28.6%, 38.4%, 42.4% vs 14.8% placebo
  • Diarrhoea: 25.2%, 34.1%, 32.0% vs 13.5% placebo
  • Constipation: 23.8%, 25.9%, 26.1% vs 10.9% placebo
  • Vomiting: 10.6%, 22.8%, 25.3% vs 4.8% placebo

These events clustered during dose escalation, were predominantly mild to moderate, and were partially mitigated by a lower starting dose. That pattern will be familiar to anyone who has used semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) in Australia — the titration period is where most of the trouble sits.

Discontinuation is where the dose really shows

The number that matters clinically is how many people stopped. In TRIUMPH-1, discontinuation due to adverse events tracked the dose: 4.1% at 4 mg, 6.9% at 9 mg and 11.3% at 12 mg, versus 4.9% on placebo. In TRIUMPH-4, the figures were higher again — 12.2% at 9 mg and 18.2% at 12 mg, against 4.0% on placebo.

So at the 12 mg dose that produced the headline weight loss — around 28.7% at 68 weeks in TRIUMPH-4, and up to roughly 28.3% over 80 weeks in TRIUMPH-1 — somewhere between one in nine and one in five participants left the trial because of side effects, depending on the study population. That is the trade-off the headline percentages don't show, and it's worth reading alongside our safety overview.

Why this matters in an Australian context

Australia has no approved label for retatrutide and no TGA evaluation underway that has been publicly confirmed. Lilly has indicated it plans to begin regulatory filings from 2027. That means the risk information Australian prescribers would normally rely on — an approved Product Information document, with adverse reactions listed by frequency and any required monitoring — simply does not exist here yet. Whether dysesthesia ends up in a label, and with what wording, is a decision regulators haven't made.

One practical point that does apply now: the TGA runs the Database of Adverse Event Notifications (DAEN) and accepts reports from consumers as well as health professionals, including reports about unapproved medicines and products obtained from overseas. Reports can be lodged on the TGA website or by phoning 1300 MEDICINE (1300 633 424). Adverse events under the Special Access Scheme or Authorised Prescriber pathway carry their own separate reporting obligations.

If you want the Australian regulatory picture, we track it on our Australia page, and the mechanism behind the three-receptor design is explained in what is retatrutide.

Join the free updates list to get the full TRIUMPH safety data the moment it's peer-reviewed and published.

FAQ

What are the side effects of retatrutide?

In phase 3 TRIUMPH trials the most common were gastrointestinal — nausea (up to 42.4% at 12 mg vs 14.8% on placebo), diarrhoea, constipation and vomiting — mostly during dose escalation and predominantly mild to moderate. Phase 3 also surfaced dysesthesia, an altered sense of touch, in 20.9% of the 12 mg group in TRIUMPH-4.

What is dysesthesia and is it serious?

Dysesthesia is abnormal or unpleasant sensation — tingling, burning, numbness or heightened skin sensitivity. Lilly has described the events in TRIUMPH-4 as generally mild and said they did not appear to lead to discontinuation, but that is topline company data and the full peer-reviewed severity and resolution details were still pending.

Are retatrutide side effects worse than Ozempic or Mounjaro?

No head-to-head trial has been published comparing retatrutide's tolerability directly with semaglutide or tirzepatide, so a fair comparison isn't available. What the trial data does show is a clear dose relationship within retatrutide itself, with discontinuation rising from 4.1% at 4 mg to 11.3% at 12 mg in TRIUMPH-1.

Can I report a side effect to the TGA in Australia?

Yes. The TGA accepts adverse event reports from consumers and health professionals through its website or on 1300 MEDICINE (1300 633 424), including reports about unapproved medicines and products sourced from overseas. Reports are investigated and published in the Database of Adverse Event Notifications.

Sources

This article is for general information only and is not medical advice. Retatrutide is an investigational drug and is not approved by the TGA for any use in Australia. Speak to a qualified Australian health professional about your own circumstances. retatrutide.net.au is an independent information site and is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.